Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs James Hardie Industries plc. Ordinary Shares (JHX) Price & Performance

GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.

The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.

James Hardie Industries (JHX) trades at $24.67, down 0.36% with a bearish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 112.14 but strong revenue growth from $3.88B to $5.4B projected. Recent earnings beat expectations in Q2 2026, and the company completed strategic divestitures including the $980M Fermacell sale to Holcim. Analyst sentiment remains positive with 70.59% buy ratings and a $34 consensus price target representing 38% upside potential.

JHX presents a growth story with expanding revenues but faces profitability compression as net margins decline from 10.93% to 2.69%. The stock's high valuation multiples require strong execution to justify. Key risks include integration challenges from recent acquisitions, rising debt levels, and housing market sensitivity. Institutional ownership shows mixed signals with State Street reducing its position while short interest increased 47.8% in September 2026.